Physician profile
Robert A Jackson
NPI 1114076882
$1,146.36
in general payments reported to CMS, 2019-2025
19 companies · $29.47 in 2025
The $29.47 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $331 · 2023: $360 · 2024: $19.82 · 2025: $29.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $339.65 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $171.76 | 2021 | |
| Novo Nordisk INC | $124.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $115.30 | 2022-2023 | Calquence |
| Xeris Pharmaceuticals, INC. | $107.98 | 2023 | Gvoke Hypopen |
| Collegium Pharmaceutical, INC. | $90.82 | 2021 | |
| Pacira Therapeutics, INC. | $81.56 | 2021 | |
| Astellas Pharma US INC | $69.99 | 2023 | |
| Abbott Laboratories | $61.63 | 2021-2022 | |
| Lilly USA, LLC | $53.35 | 2022-2023 | Jaypirca |
| Pacira Pharmaceuticals Incorporated | $50.81 | 2022-2024 | Exparel |
| Amgen INC. | $42.01 | 2023 | Kyprolis, Lumakras |
| Pfizer INC. | $31.92 | 2021-2023 | |
| Intrinsic Therapeutics | $29.47 | 2025 | Barricaid Acd (Annular Closure Device) |
| Rigel Pharmaceuticals, INC. | $23.72 | 2023 | Rezlidhia, Tavalisse |
| La Jolla Pharmaceutical Company | $22.13 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $20.57 | 2023 | Orserdu |
| Novartis Pharmaceuticals Corporation | $19.08 | 2023 | |
| Puma Biotechnology, INC. | $15.35 | 2023 | |
| Merck Sharp & Dohme LLC | $13.92 | 2023 | Keytruda, Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.